Effect of Liraglutide (Victoza) on Inflammation in Human Adipose Tissue and Blood

Inclusion Criteria:

   - BMI between 25 and 42 kg/m2

   - Diet-controlled diabetics, or diabetics on Metformin that have permission from Primacy
   Care Physician to wash-out of the drug for 6 weeks prior to the study and for the
   duration of the study

   - HbA1C between 6.0 - 7.9 (those on Metformin must have a HbA1c level below 7.5 prior to
   wash-out period)

   - Fasting Blood Glucose < 150 mg/dl

   - Women must be post-menopausal or surgically sterile within age range

   - Subjects must live in vicinity of Stanford University

Exclusion Criteria:

   - Prior Bariatric surgery

   - Personal or family history of medullary thyroid cancer

   - MEN2 Syndrome

   - Thyroid Nodules (not evaluated by PCP)

   - Pancreatitis (acute or chronic)

   - Gallstones

   - Fasting plasma triglycerides > 400 mg/dl

   - Cardiovascular disease

   - Major organ disease

   - Unstable hypertension (BP >160/100 mm Hg)

   - Heavy alcohol use

   - Self-reported weight change of >2kg over past 6 weeks

   - Medication known to affect blood glucose, insulin sensitivity, or inflammation

   - NSAIDs (must cease use 4 weeks prior to study enrollment)

   - Previous use of liraglutide, Januvia, Byetta, or Lira.